Evidence and Practice
Why you should read this article: • To enhance your knowledge of adrenal incidentaloma and the issues that patients with this condition may experience • To understand how digital technology could be used to support patients newly diagnosed with long-term conditions • To identify how online and web-based information and support programmes could be adapted to support patients with adrenal incidentaloma An adrenal incidentaloma is a mass discovered on the adrenal glands when patients have an investigative scan for an unrelated reason, and is considered a long-term condition. Online resources for people with other long-term conditions can provide information and advice on self-management, which can reduce their stress and anxiety. This article reports findings of a literature review on the effectiveness of using digital technology and digital communication methods to support patients newly diagnosed with a long-term condition. No evidence was found on this topic in relation to adrenal incidentaloma, so the literature on other long-term conditions – specifically cancer, diabetes mellitus and human immunodeficiency virus (HIV) – was reviewed. The article suggests that, despite the limited data on digital technology to support newly diagnosed patients with adrenal incidentaloma, online and web-based information and support programmes are used successfully for patients with other long-term conditions. Therefore, these programmes could be adapted or developed for this patient group.
The role of society and culture in influencing what is seen as a Western male grief response
Findings from a study of a digital tool to support people with multiple myeloma
Second of two articles describing the personal story of cancer
Literature review on enhanced recovery in patients undergoing colorectal surgery
Qualitative research into prostate cancer among black men in England
Use of CDK4 and CDK6 inhibitors in patients with breast cancer
Oral complications can cause distress, long-term complications and increased morbidity
A systematic approach for nurses at any level or experience to engage with service evaluation
Receiving a new diagnosis of cancer or of its recurrence is distressing and there are increasing numbers of people living with the disease, some taking continuous treatment, as well as others who have been cured. Living with cancer and the possibility of recurrence requires psychological strength to deal with the treatment, effects of the illness and uncertainty about the future. The attributes of self-efficacy and psychological well-being can reduce the effects of chronic stress. Excellent symptom control is essential and fatigue, the most prevalent and often most distressing symptom for those with cancer, requires targeted support. Well-being and psychological resilience may be improved by specific actions and psychological approaches, some of which are encompassed by Foresight Mental Capital and Well-being Project’s (2008) five ways to well-being framework, which can be used to deliver personalised care. This is the second of a two-part article that reviews interventions promoting well-being and resilience in patients living with cancer. It describes the framework and suggests practical ways in which clinicians can integrate it and other interventions into clinical practice. It also offers time out exercises and a multiple choice quiz to aid readers’ learning and test their knowledge.
There is increasing recognition of the importance of making the Recovery Package available to more people affected by cancer. The cancer treatment summary is one of the core components of the Recovery Package and aims to improve communication between secondary and primary care, and help patients manage their care following treatment. The Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance is developing a suite of best practice treatment summary templates for each cancer site to improve the quality of the information in the documents, and to support cancer teams to begin the process of introducing them to practice.
Oral vinorelbine has been a well-established cytotoxic treatment for non-small cell lung cancer and metastatic breast cancer since 2004. This article summarises the applications of the drug, the advantages and challenges of using an oral agent in palliative oncology settings and how oral vinorelbine has been used to develop nurse-led services and chemotherapy outside traditional hospital environments. The article includes two case studies to place this treatment in a clinical context.